Anticancer fusion protein

The fusion protein, especially recombinant, comprising domain (a) which is a functional fragment of soluble hTRAIL protein sequence beginning with an amino acid at a position not lower than hTRAIL95 or a sequence having at least 70% homology thereto; and domain (b) which is a sequence of pro-apoptot...

Full description

Saved in:
Bibliographic Details
Main Authors PIECZYKOLAN, JERZY SZCZEPAN, ZEREK, BARTLOMIEJ MACIEJ, PAWLAK, SEBASTIAN DOMINIK, LEMKE, KRZYSZTOF KAZIMIERZ
Format Patent
LanguageEnglish
Published 10.01.2013
Subjects
CHEMISTRY
METALLURGY
ORGANIC CHEMISTRY
PEPTIDES
Online AccessGet full text

Cover

More Information
Summary:The fusion protein, especially recombinant, comprising domain (a) which is a functional fragment of soluble hTRAIL protein sequence beginning with an amino acid at a position not lower than hTRAIL95 or a sequence having at least 70% homology thereto; and domain (b) which is a sequence of pro-apoptotic effector peptide, wherein the sequence of domain (b) is attached at C- terminus and/or N - terminus of domain (a). The fusion protein has anticancer activity. The nucleotide sequence coding the fusion protein, expression vector and host cell for the preparation of the fusion protein, and the use of the fusion protein for treating cancer diseases.
Bibliography:Application Number: AU20110268876